Evaluation of diagnostiC Capacity of eccDNAs as Biomarkers in Indetermined biLiary Stricture(ECCBILE)

Launched by PEKING UNIVERSITY THIRD HOSPITAL · Feb 19, 2024

Keywords

ClinConnect Summary

The clinical trial named ECCBILE is studying a new way to help doctors better understand certain bile duct issues, specifically when they are unsure if the problem is caused by cancer. This trial focuses on a type of DNA found in the bloodstream called eccDNA, which may be able to indicate whether a patient has a malignant (cancerous) biliary stricture. Currently, the usual methods for diagnosing these issues during a procedure called endoscopic retrograde cholangiopancreatography (ERCP) are not very accurate. The hope is that using eccDNA could improve the chances of early and correct diagnosis, which is crucial for better patient outcomes.

To participate in this trial, patients should be between the ages of 65 and 74 and have suspected biliary strictures that require ERCP. Those who have experienced a failed ERCP, have serious other health issues, or are expected to live less than a year due to other diseases may not be eligible. Participants can expect to undergo standard procedures during their diagnosis, but they will also provide blood samples for the study to assess the potential of eccDNA as a diagnostic tool. This trial is currently recruiting participants and aims to gather more evidence on this promising new approach.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients is suspected indetermined biliary strictures
• • Patients have the indication for ERCP
• Exclusion Criteria:
• • ERCP failed, or can not obtain bile
• • Sever comorbidities
• • Predicted overall survival less than 1 year because of other disease
• • Patients who are unlikely to comply with the protocol, inability to return for subsequent visits